Asia Pac HealthTech ecosystem momentum continues unabated closing at the mid year point at US$2.5B invested, building on the back of a record breaking 2018. Early stage ventures deal activity shrinks yet further, whereas total Series B and C deal value continues to grow, grabbing 69% of total funding, raising questions regarding the sustainability of the deal flow of Growth stage investors.

About our Premium Reports

Our Premium Reports are specialized reports that are only available to active users with HealthTech Alpha Pro and HealthTech Alpha Enterprise accounts and are provided at no additional cost.

Source of Data

Galen Growth’s proprietary platform, HealthTech Alpha, provides the data source for this report. Corporate Business Development, Business Intelligence, and Digital Health Partnership teams worldwide prefer HealthTech Alpha, the world’s most-trusted Digital Health data, intel, and insights platform. Visit https://www.healthtechalpha.com to learn more about our data or https://www.galengrowth.com research for our reports.

Our Mission

Founded in 2016 by Digital Health experts, Galen Growth empowers global Fortune 500 companies, institutional investors, and promising Digital Health ventures to fast track their digital health strategy to create significant financial and social values. To find out more, visit https://www.galengrowth.com

Free

BASIC

  • Download the report headlines
  • Access to limited data in HealthTech Alpha
Free
View
Recommended

PRO

  • Sign up now to download all premium research
  • Access and download all data in HealthTech Alpha
$ 385 /Month
Pro
Custom Solution

Enterprise

  • Get full access to unmatched premium research for your organization
  • Additional collaboration features to take your team's research and collaboration to the next level
Let's Talk
Contact Us

© Galen Growth 2024

Overview

Category

Stage

Total Funding

GGA Score

powered by